Murphy-Ullrich et al., Vol. 115, No. 4, 1127–1136. Due to an author's error, the following information on the mAbs was omitted from the paper.

mAb 81C6 has been characterized previously as binding to human tenascin (1, 2, 4). This antibody, and the U-251 MG-(clone 3) cell line used to produce human tenascin, were generously provided by Dr. D. D. Bigner (Department of Pathology, Duke University Medical Center). mAb 127 has previously been studied and shown to bind to an epitope in the alternatively spliced region of human and chicken tenascin (3).

References

1. Bourdon, M. A., C. J. Wikstrand, H. Furthmayr, T. J. Matthews, and D. D. Bigner. 1983. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. *Cancer Res.* 43:2796–2805.
2. Erickson, H. P., and H. C. Taylor. 1987. Hexabrachion proteins in embryonic chicken tissues and human tumors. *J. Cell Biol.* 105:1387–1394.
3. Lightner, V. A., C. Pegram, D. Bigner, and H. P. Erickson. 1989. Monoclonal antibody 127 recognizes a subpopulation of chicken hexabrachion/tenascin. *In* Cytoskeletal and Extracellular Matrix Proteins. Aebi, U., and J. Engel, editors. Springer-Verlag, Berlin. 114–116.
4. Zalutsky, M. R., R. P. Moseley, H. B. Coakham, R. E. Coleman, and D. D. Bigner. 1989. Pharmacokinetics and tumor localization of ^{131}I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. *Cancer Res.* 49:2807–2813.

Downloaded from http://rupress.org/jcb/article-pdf/116/3/833/1468619/833.pdf by guest on 08 February 2026